Table 4.
Simultaneous analysis of all possible predictors of endocrine toxicity by binary logistic regression analysis
| Statistical significance | Odd ratio | Odd Ratio C.I. (95%) | Probability | Probability C.I. (95%) | ||||
|---|---|---|---|---|---|---|---|---|
| Lower | Upper | Lower | Upper | |||||
| Gender | Male | 0.074 | 1.717 | 0.95 | 3.103 | 0.233 | 0.215 | 0.250 |
| Female | 0.365 | 0.334 | 0.395 | |||||
| Tumor | NSCLC | 0.284 | 0.799 | 0.53 | 1.204 | 0.298 | 0.277 | 0.320 |
| Melanoma | 0.247 | 0.215 | 0.279 | |||||
| Kidney | 0.276 | 0.189 | 0.363 | |||||
| Breast | 0.320 | 0.177 | 0.464 | |||||
| Head-Neck | 0.125 | 0.073 | 0.177 | |||||
| Bladder | 0.120 | 0.120 | 0.120 | |||||
| Previous endocrinopathy | No | <0.001 | 4.156 | 2.141 | 8.065 | 0.216 | 0.209 | 0.223 |
| Yes | 0.539 | 0.518 | 0.560 | |||||
| Anti PD-1 | Pembrolizumab | 0.902 | 1.039 | 0.57 | 1.894 | 0.289 | 0.260 | 0.318 |
| Nivolumab | 0.279 | 0.257 | 0.302 | |||||
| Age | ≤50 | 0.683 | 0.958 | 0.782 | 1.175 | 0.289 | 0.207 | 0.372 |
| 51–55 | 0.250 | 0.214 | 0.285 | |||||
| 56–60 | 0.278 | 0.217 | 0.340 | |||||
| 61–65 | 0.311 | 0.258 | 0.363 | |||||
| 66–70 | 0.270 | 0.227 | 0.312 | |||||
| >70 | 0.286 | 0.260 | 0.311 | |||||
A result is considered statistically significant if it allows to reject the null hypothesis. A significance level of 5% was considered, namely all the results with a p value < 0.05 have a 5% probability that the null hypothesis is correct. Conversely, the same results have a 95% probability that the expected result is correct
C.I. Confidence Interval